Background: Proton pump inhibitors (PPIs) are effective treatments for gastrointestinal conditions. Recent evidence suggests they are often prescribed inappropriately or for longer than necessary. PPIs have also been associated with increased risk of kidney disease and dementia. Older people are particularly vulnerable to potential adverse affects. Methods: An audit was performed in April 2016 and a reaudit was completed in January 2017. Patients over 65 on general medical and surgical wards were included. The audit recorded PPI use, dose, regimen, and concominant use of medications increasing risk of peptic ulcer disease, gastrointestinal bleeding or dyspepsia. The medical notes were reviewed to identify valid indications for PPI prescriptions in accordance with international guidance and best evidence. Prior to reaudit, recommendations were communicated at Grand Rounds, specialty meetings and by email. Results: 181 inpatients were included in the first audit iteration and 179 in the reaudit. The mean age was 80 years in both cohorts. There was a reduction in patients prescribed a PPI, from 68% to 53.1% (p = 0.004). At reaudit, 83.2% of patients had a valid indication compared to 77.2% (p = 0.28). The most common indication was prophylaxis of NSAID-induced gastric and duodenal ulcers (54.4%). The remaining indications for PPI prescription were GORD or Barrett's Oesophagitis (16.5%), PUD (11.4%), gastritis (13.9%), and GI bleeding (1.3%). Conclusions: Following the intervention, there were fewer patients prescribed a PPI and more of those on a PPI had an identifiable indication. More accurate PPI prescribing may result in less adverse effects and reduced hospital drug expenditure. iii13
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